LIQUID BIOPSIES, EXOSOMES AND CFDNA ISOLATION
CBI offers prospective collection of plasma samples from patients, kits and reagents for efficient isolation of circulating exosomes and cell-free DNA (cfDNA) from liquid biopsies. Our SubX® cfDNA isolation kits have been specifically developed for efficient recovery of small DNA fragments. SubX®-Exo-DNA kit is designed for simultaneous isolation of exosomes and cfDNA directly from liquid biopsies (plasma or serum) without Proteinase K.
Introducing the SubX® Plasma cfDNA and SubX®-Exo-DNA Isolation Kits - Liquid Biopsy Made Easy
A method for fast and effective biding of DNA to solid phase matrix in physiological conditions (directly in bio-liquids)
Unbiased isolation of DNA fragments
No dilution of the starting material is required
Order Full cfDNA Kit (
List Price:$580/Discounted Price:$395)
Order Full Exo-DNA Kit (
List Price:$595/Discounted Price:$395)
The DNA-binding SubX® matrix allows:
• Flexibility. Scaling up of the procedure to 50 ml of starting material or scaling down to extra-low volumes as well as adaptation of the protocol for 96- or 384-well formats
• Efficiency. Separation of cfDNA from the bulk of proteins in a single vortex-spin step without employing chaotropic agents allows you to speed-up the isolation procedure to save time and overall costs
• Adaptability. Effectively bind cell-free DNA of virtually any size ranging from 100 Kbp down to 50 bp therefore extending downstream applications
Cell-free circulating DNA was discovered in 1948 but only recently has begun to attract the widespread attention of researchers. Historically, tumor tissue was considered as the major source of tumor DNA and thus invasive biopsy was the only way of obtaining such materials. Later, it was discovered that dying tumor cells release small pieces of their DNA into the bloodstream. These pieces are called cell-free circulating tumor DNA (ctDNA).
ctDNA has been detected in most types of cancer, even during early stages, suggesting the analysis of ctDNA at every stage of cancer may be used in personalized patient care. Thus, measurement of ctDNA levels in blood and identification of specific mutations in certain genes may also be used for estimation of cancer stage development and prognosis.